Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention

Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and thrombolysis 2010-10, Vol.30 (3), p.347-353
Hauptverfasser: Dudek, Dariusz, Rakowski, Tomasz, Bartus, Stanislaw, Giszterowicz, Dawid, Dobrowolski, Wojciech, Zmudka, Krzysztof, Zalewski, Jaroslaw, Ochala, Andrzej, Wieja, Pawel, Janus, Bogdan, Dziewierz, Artur, Legutko, Jacek, Bryniarski, Leszek, Dubiel, Jacek S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose. We investigated the role of early abciximab administration on top of early clopidogrel 600 mg loading dose in patients with STEMI treated with PPCI. A total of 73 non-shock STEMI 
ISSN:0929-5305
1573-742X
DOI:10.1007/s11239-010-0461-9